Neutrophil	B:C0027950
and	O
Monocyte	O
Function	O
in	O
Patients	O
with	O
Chronic	O
Hepatitis	I:C0524910
C	I:C0524910
Undergoing	O
Antiviral	O
Therapy	I:C0280274
with	O
Regimens	O
Containing	O
Protease	O
Inhibitors	I:C0033607
with	O
and	O
without	O
Interferon	O
.	O

Neutrophil	O
and	O
Monocyte	B:C0026473
Function	O
in	O
Patients	O
with	O
Chronic	O
Hepatitis	I:C0524910
C	I:C0524910
Undergoing	O
Antiviral	O
Therapy	I:C0280274
with	O
Regimens	O
Containing	O
Protease	O
Inhibitors	I:C0033607
with	O
and	O
without	O
Interferon	O
.	O

Neutrophil	O
and	O
Monocyte	O
Function	B:C0007613
in	O
Patients	O
with	O
Chronic	O
Hepatitis	I:C0524910
C	I:C0524910
Undergoing	O
Antiviral	O
Therapy	I:C0280274
with	O
Regimens	O
Containing	O
Protease	O
Inhibitors	I:C0033607
with	O
and	O
without	O
Interferon	O
.	O

Neutrophil	O
and	O
Monocyte	O
Function	O
in	O
Patients	O
with	O
Chronic	B:C0524910
Hepatitis	I:C0524910
C	I:C0524910
Undergoing	O
Antiviral	O
Therapy	I:C0280274
with	O
Regimens	O
Containing	O
Protease	O
Inhibitors	I:C0033607
with	O
and	O
without	O
Interferon	O
.	O

Neutrophil	O
and	O
Monocyte	O
Function	O
in	O
Patients	O
with	O
Chronic	O
Hepatitis	I:C0524910
C	I:C0524910
Undergoing	O
Antiviral	B:C0280274
Therapy	I:C0280274
with	O
Regimens	O
Containing	O
Protease	O
Inhibitors	I:C0033607
with	O
and	O
without	O
Interferon	O
.	O

Neutrophil	O
and	O
Monocyte	O
Function	O
in	O
Patients	O
with	O
Chronic	O
Hepatitis	I:C0524910
C	I:C0524910
Undergoing	O
Antiviral	O
Therapy	I:C0280274
with	O
Regimens	B:C0040808
Containing	O
Protease	O
Inhibitors	I:C0033607
with	O
and	O
without	O
Interferon	O
.	O

Neutrophil	O
and	O
Monocyte	O
Function	O
in	O
Patients	O
with	O
Chronic	O
Hepatitis	I:C0524910
C	I:C0524910
Undergoing	O
Antiviral	O
Therapy	I:C0280274
with	O
Regimens	O
Containing	O
Protease	B:C0033607
Inhibitors	I:C0033607
with	O
and	O
without	O
Interferon	O
.	O

Neutrophil	O
and	O
Monocyte	O
Function	O
in	O
Patients	O
with	O
Chronic	O
Hepatitis	I:C0524910
C	I:C0524910
Undergoing	O
Antiviral	O
Therapy	I:C0280274
with	O
Regimens	O
Containing	O
Protease	O
Inhibitors	I:C0033607
with	O
and	O
without	O
Interferon	B:C0021747
.	O

Real	O
-	O
life	O
data	O
showed	O
an	O
increased	O
incidence	O
of	O
bacterial	B:C0004623
infections	I:C0004623
in	O
patients	O
with	O
advanced	O
liver	O
disease	I:C0023895
receiving	O
a	O
protease	O
inhibitor	I:C0033607
(	O
protease	O
inhibitor	I:C0033607
)	O
-	O
containing	O
antiviral	O
regimen	I:C0040808
against	O
hepatitis	O
C	I:C0220847
(	O
HCV	O
)	O
.	O

Real	O
-	O
life	O
data	O
showed	O
an	O
increased	O
incidence	O
of	O
bacterial	O
infections	I:C0004623
in	O
patients	O
with	O
advanced	O
liver	B:C0023895
disease	I:C0023895
receiving	O
a	O
protease	O
inhibitor	I:C0033607
(	O
protease	O
inhibitor	I:C0033607
)	O
-	O
containing	O
antiviral	O
regimen	I:C0040808
against	O
hepatitis	O
C	I:C0220847
(	O
HCV	O
)	O
.	O

Real	O
-	O
life	O
data	O
showed	O
an	O
increased	O
incidence	O
of	O
bacterial	O
infections	I:C0004623
in	O
patients	O
with	O
advanced	O
liver	O
disease	I:C0023895
receiving	O
a	O
protease	B:C0033607
inhibitor	I:C0033607
(	O
protease	O
inhibitor	I:C0033607
)	O
-	O
containing	O
antiviral	O
regimen	I:C0040808
against	O
hepatitis	O
C	I:C0220847
(	O
HCV	O
)	O
.	O

Real	O
-	O
life	O
data	O
showed	O
an	O
increased	O
incidence	O
of	O
bacterial	O
infections	I:C0004623
in	O
patients	O
with	O
advanced	O
liver	O
disease	I:C0023895
receiving	O
a	O
protease	O
inhibitor	I:C0033607
(	O
protease	B:C0033607
inhibitor	I:C0033607
)	O
-	O
containing	O
antiviral	O
regimen	I:C0040808
against	O
hepatitis	O
C	I:C0220847
(	O
HCV	O
)	O
.	O

Real	O
-	O
life	O
data	O
showed	O
an	O
increased	O
incidence	O
of	O
bacterial	O
infections	I:C0004623
in	O
patients	O
with	O
advanced	O
liver	O
disease	I:C0023895
receiving	O
a	O
protease	O
inhibitor	I:C0033607
(	O
protease	O
inhibitor	I:C0033607
)	O
-	O
containing	O
antiviral	B:C0040808
regimen	I:C0040808
against	O
hepatitis	O
C	I:C0220847
(	O
HCV	O
)	O
.	O

Real	O
-	O
life	O
data	O
showed	O
an	O
increased	O
incidence	O
of	O
bacterial	O
infections	I:C0004623
in	O
patients	O
with	O
advanced	O
liver	O
disease	I:C0023895
receiving	O
a	O
protease	O
inhibitor	I:C0033607
(	O
protease	O
inhibitor	I:C0033607
)	O
-	O
containing	O
antiviral	O
regimen	I:C0040808
against	O
hepatitis	B:C0220847
C	I:C0220847
(	O
HCV	O
)	O
.	O

Real	O
-	O
life	O
data	O
showed	O
an	O
increased	O
incidence	O
of	O
bacterial	O
infections	I:C0004623
in	O
patients	O
with	O
advanced	O
liver	O
disease	I:C0023895
receiving	O
a	O
protease	O
inhibitor	I:C0033607
(	O
protease	O
inhibitor	I:C0033607
)	O
-	O
containing	O
antiviral	O
regimen	I:C0040808
against	O
hepatitis	O
C	I:C0220847
(	O
HCV	B:C0220847
)	O
.	O

We	O
hypothesized	O
that	O
PIs	B:C0033607
might	O
impair	O
innate	O
immune	O
responses	O
through	O
the	O
inhibition	O
of	I:C1524081
proteases	I:C1524081
participating	O
in	O
the	O
anti-bacterial	O
functions	I:C0544570
of	O
neutrophils	O
and	O
monocytes	O
.	O

We	O
hypothesized	O
that	O
PIs	O
might	O
impair	O
innate	O
immune	O
responses	O
through	O
the	O
inhibition	B:C1524081
of	I:C1524081
proteases	I:C1524081
participating	O
in	O
the	O
anti-bacterial	O
functions	I:C0544570
of	O
neutrophils	O
and	O
monocytes	O
.	O

We	O
hypothesized	O
that	O
PIs	O
might	O
impair	O
innate	O
immune	O
responses	O
through	O
the	O
inhibition	O
of	I:C1524081
proteases	I:C1524081
participating	O
in	O
the	O
anti-bacterial	B:C0544570
functions	I:C0544570
of	O
neutrophils	O
and	O
monocytes	O
.	O

We	O
hypothesized	O
that	O
PIs	O
might	O
impair	O
innate	O
immune	O
responses	O
through	O
the	O
inhibition	O
of	I:C1524081
proteases	I:C1524081
participating	O
in	O
the	O
anti-bacterial	O
functions	I:C0544570
of	O
neutrophils	B:C0027950
and	O
monocytes	O
.	O

We	O
hypothesized	O
that	O
PIs	O
might	O
impair	O
innate	O
immune	O
responses	O
through	O
the	O
inhibition	O
of	I:C1524081
proteases	I:C1524081
participating	O
in	O
the	O
anti-bacterial	O
functions	I:C0544570
of	O
neutrophils	O
and	O
monocytes	B:C0026473
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	O
phagocytic	B:C0085416
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
neutrophils	O
and	O
monocytes	O
obtained	O
from	O
patients	O
receiving	O
a	O
protease	O
inhibitor	I:C0033607
containing	O
-	O
antiviral	O
regimen	I:C0040808
,	O
and	O
to	O
determine	O
cytokine	O
secretion	I:C1327414
after	O
neutrophil	O
stimulation	O
with	O
flagellin	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
neutrophils	B:C0027950
and	O
monocytes	O
obtained	O
from	O
patients	O
receiving	O
a	O
protease	O
inhibitor	I:C0033607
containing	O
-	O
antiviral	O
regimen	I:C0040808
,	O
and	O
to	O
determine	O
cytokine	O
secretion	I:C1327414
after	O
neutrophil	O
stimulation	O
with	O
flagellin	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
neutrophils	O
and	O
monocytes	B:C0026473
obtained	O
from	O
patients	O
receiving	O
a	O
protease	O
inhibitor	I:C0033607
containing	O
-	O
antiviral	O
regimen	I:C0040808
,	O
and	O
to	O
determine	O
cytokine	O
secretion	I:C1327414
after	O
neutrophil	O
stimulation	O
with	O
flagellin	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
neutrophils	O
and	O
monocytes	O
obtained	O
from	O
patients	O
receiving	O
a	O
protease	B:C0033607
inhibitor	I:C0033607
containing	O
-	O
antiviral	O
regimen	I:C0040808
,	O
and	O
to	O
determine	O
cytokine	O
secretion	I:C1327414
after	O
neutrophil	O
stimulation	O
with	O
flagellin	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
neutrophils	O
and	O
monocytes	O
obtained	O
from	O
patients	O
receiving	O
a	O
protease	O
inhibitor	I:C0033607
containing	O
-	O
antiviral	B:C0040808
regimen	I:C0040808
,	O
and	O
to	O
determine	O
cytokine	O
secretion	I:C1327414
after	O
neutrophil	O
stimulation	O
with	O
flagellin	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
neutrophils	O
and	O
monocytes	O
obtained	O
from	O
patients	O
receiving	O
a	O
protease	O
inhibitor	I:C0033607
containing	O
-	O
antiviral	O
regimen	I:C0040808
,	O
and	O
to	O
determine	O
cytokine	B:C1327414
secretion	I:C1327414
after	O
neutrophil	O
stimulation	O
with	O
flagellin	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
neutrophils	O
and	O
monocytes	O
obtained	O
from	O
patients	O
receiving	O
a	O
protease	O
inhibitor	I:C0033607
containing	O
-	O
antiviral	O
regimen	I:C0040808
,	O
and	O
to	O
determine	O
cytokine	O
secretion	I:C1327414
after	O
neutrophil	B:C0027950
stimulation	O
with	O
flagellin	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
neutrophils	O
and	O
monocytes	O
obtained	O
from	O
patients	O
receiving	O
a	O
protease	O
inhibitor	I:C0033607
containing	O
-	O
antiviral	O
regimen	I:C0040808
,	O
and	O
to	O
determine	O
cytokine	O
secretion	I:C1327414
after	O
neutrophil	O
stimulation	B:C0007613
with	O
flagellin	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
neutrophils	O
and	O
monocytes	O
obtained	O
from	O
patients	O
receiving	O
a	O
protease	O
inhibitor	I:C0033607
containing	O
-	O
antiviral	O
regimen	I:C0040808
,	O
and	O
to	O
determine	O
cytokine	O
secretion	I:C1327414
after	O
neutrophil	O
stimulation	O
with	O
flagellin	B:C0016194
.	O

Forty	O
patients	O
with	O
chronic	B:C0524910
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	B:C0023890
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	B:C0087111
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	B:C0441835
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	B:C0021747
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	B:C0035525
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	B:C0033607
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	B:C1876229
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	B:C1738934
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	B:C2605855
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	B:C0040808
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	B:C0008902
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	B:C2605855
and	O
sofosbuvir	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	I:C0524910
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	I:C0087111
(	O
Group	O
A	I:C0441835
)	O
with	O
pegylated	O
-	I:C0021747
interferon	I:C0021747
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	I:C0033607
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-	I:C0040808
free	I:C0040808
regimen	I:C0040808
(	O
Group	O
B	I:C0008902
)	O
with	O
simeprevir	O
and	O
sofosbuvir	B:C2976303
.	O

Phagocytosis	B:C0085416
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
were	O
analyzed	O
by	O
flow	O
cytometry	I:C0016263
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
of	O
therapy	O
.	O

Phagocytosis	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
were	O
analyzed	O
by	O
flow	B:C0016263
cytometry	I:C0016263
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
of	O
therapy	O
.	O

Phagocytosis	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
were	O
analyzed	O
by	O
flow	O
cytometry	I:C0016263
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
of	O
therapy	B:C0087111
.	O

In	O
neutrophils	B:C0027950
from	O
Group	O
A	I:C0441835
patients	O
,	O
oxidative	O
burst	I:C0085416
rate	O
and	O
oxidative	O
enzymatic	O
activity	I:C2267219
per	I:C2267219
cell	I:C2267219
significantly	O
decreased	O
throughout	O
the	O
study	O
period	O
(	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.010	O
,	O
respectively	O
)	O
.	O

In	O
neutrophils	O
from	O
Group	B:C0441835
A	I:C0441835
patients	O
,	O
oxidative	O
burst	I:C0085416
rate	O
and	O
oxidative	O
enzymatic	O
activity	I:C2267219
per	I:C2267219
cell	I:C2267219
significantly	O
decreased	O
throughout	O
the	O
study	O
period	O
(	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.010	O
,	O
respectively	O
)	O
.	O

In	O
neutrophils	O
from	O
Group	O
A	I:C0441835
patients	O
,	O
oxidative	B:C0085416
burst	I:C0085416
rate	O
and	O
oxidative	O
enzymatic	O
activity	I:C2267219
per	I:C2267219
cell	I:C2267219
significantly	O
decreased	O
throughout	O
the	O
study	O
period	O
(	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.010	O
,	O
respectively	O
)	O
.	O

In	O
neutrophils	O
from	O
Group	O
A	I:C0441835
patients	O
,	O
oxidative	O
burst	I:C0085416
rate	O
and	O
oxidative	O
enzymatic	B:C2267219
activity	I:C2267219
per	I:C2267219
cell	I:C2267219
significantly	O
decreased	O
throughout	O
the	O
study	O
period	O
(	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.010	O
,	O
respectively	O
)	O
.	O

Pairwise	O
comparisons	O
showed	O
a	O
decrease	O
between	O
baseline	O
and	O
week	O
4	O
and	O
8	O
of	O
therapy	B:C0087111
.	O

No	O
differences	O
were	O
observed	O
after	O
the	O
introduction	B:C1293116
of	O
the	O
protease	O
inhibitor	I:C0033607
.	O

No	O
differences	O
were	O
observed	O
after	O
the	O
introduction	O
of	O
the	O
protease	B:C0033607
inhibitor	I:C0033607
.	O

The	O
oxidative	O
enzymatic	B:C2267219
activity	I:C2267219
per	I:C2267219
cell	I:C2267219
in	O
monocytes	O
significantly	O
decrease	O
during	O
the	O
study	O
period	O
(	O
p	O
=	O
0.042	O
)	O
due	O
to	O
a	O
decrease	O
from	O
baseline	O
to	O
week	O
8	O
of	O
therapy	O
(	O
p	O
=	O
0.037	O
)	O
in	O
patients	O
from	O
Group	O
A	I:C0441835
.	O
None	O
of	O
these	O
findings	O
were	O
observed	O
in	O
Group	O
B	I:C0008902
patients	O
.	O

The	O
oxidative	O
enzymatic	O
activity	I:C2267219
per	I:C2267219
cell	I:C2267219
in	O
monocytes	B:C0026473
significantly	O
decrease	O
during	O
the	O
study	O
period	O
(	O
p	O
=	O
0.042	O
)	O
due	O
to	O
a	O
decrease	O
from	O
baseline	O
to	O
week	O
8	O
of	O
therapy	O
(	O
p	O
=	O
0.037	O
)	O
in	O
patients	O
from	O
Group	O
A	I:C0441835
.	O
None	O
of	O
these	O
findings	O
were	O
observed	O
in	O
Group	O
B	I:C0008902
patients	O
.	O

The	O
oxidative	O
enzymatic	O
activity	I:C2267219
per	I:C2267219
cell	I:C2267219
in	O
monocytes	O
significantly	O
decrease	O
during	O
the	O
study	O
period	O
(	O
p	O
=	O
0.042	O
)	O
due	O
to	O
a	O
decrease	O
from	O
baseline	O
to	O
week	O
8	O
of	O
therapy	B:C0087111
(	O
p	O
=	O
0.037	O
)	O
in	O
patients	O
from	O
Group	O
A	I:C0441835
.	O
None	O
of	O
these	O
findings	O
were	O
observed	O
in	O
Group	O
B	I:C0008902
patients	O
.	O

The	O
oxidative	O
enzymatic	O
activity	I:C2267219
per	I:C2267219
cell	I:C2267219
in	O
monocytes	O
significantly	O
decrease	O
during	O
the	O
study	O
period	O
(	O
p	O
=	O
0.042	O
)	O
due	O
to	O
a	O
decrease	O
from	O
baseline	O
to	O
week	O
8	O
of	O
therapy	O
(	O
p	O
=	O
0.037	O
)	O
in	O
patients	O
from	O
Group	B:C0441835
A	I:C0441835
.	O
None	O
of	O
these	O
findings	O
were	O
observed	O
in	O
Group	O
B	I:C0008902
patients	O
.	O

The	O
oxidative	O
enzymatic	O
activity	I:C2267219
per	I:C2267219
cell	I:C2267219
in	O
monocytes	O
significantly	O
decrease	O
during	O
the	O
study	O
period	O
(	O
p	O
=	O
0.042	O
)	O
due	O
to	O
a	O
decrease	O
from	O
baseline	O
to	O
week	O
8	O
of	O
therapy	O
(	O
p	O
=	O
0.037	O
)	O
in	O
patients	O
from	O
Group	O
A	I:C0441835
.	O
None	O
of	O
these	O
findings	O
were	O
observed	O
in	O
Group	B:C0008902
B	I:C0008902
patients	O
.	O

Cytokine	B:C1327414
secretion	I:C1327414
did	O
not	O
significantly	O
change	O
during	O
the	O
study	O
in	O
both	O
groups	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	B:C0021747
(	O
rather	O
than	O
the	O
protease	O
inhibitor	I:C0033607
)	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	O
and	O
monocyte	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
HCV	O
-	O
related	O
advanced	O
liver	I:C0239946
fibrosis	I:C0239946
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	O
(	O
rather	O
than	O
the	O
protease	B:C0033607
inhibitor	I:C0033607
)	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	O
and	O
monocyte	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
HCV	O
-	O
related	O
advanced	O
liver	I:C0239946
fibrosis	I:C0239946
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	O
(	O
rather	O
than	O
the	O
protease	O
inhibitor	I:C0033607
)	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	B:C0027950
and	O
monocyte	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
HCV	O
-	O
related	O
advanced	O
liver	I:C0239946
fibrosis	I:C0239946
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	O
(	O
rather	O
than	O
the	O
protease	O
inhibitor	I:C0033607
)	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	O
and	O
monocyte	B:C0026473
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
HCV	O
-	O
related	O
advanced	O
liver	I:C0239946
fibrosis	I:C0239946
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	O
(	O
rather	O
than	O
the	O
protease	O
inhibitor	I:C0033607
)	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	O
and	O
monocyte	O
phagocytic	B:C0085416
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
HCV	O
-	O
related	O
advanced	O
liver	I:C0239946
fibrosis	I:C0239946
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	O
(	O
rather	O
than	O
the	O
protease	O
inhibitor	I:C0033607
)	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	O
and	O
monocyte	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
this	O
cohort	B:C0599755
of	O
patients	O
with	O
HCV	O
-	O
related	O
advanced	O
liver	I:C0239946
fibrosis	I:C0239946
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	O
(	O
rather	O
than	O
the	O
protease	O
inhibitor	I:C0033607
)	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	O
and	O
monocyte	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
HCV	B:C0220847
-	O
related	O
advanced	O
liver	I:C0239946
fibrosis	I:C0239946
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	O
(	O
rather	O
than	O
the	O
protease	O
inhibitor	I:C0033607
)	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	O
and	O
monocyte	O
phagocytic	O
and	I:C0085416
oxidative	I:C0085416
burst	I:C0085416
capacity	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
HCV	O
-	O
related	O
advanced	B:C0239946
liver	I:C0239946
fibrosis	I:C0239946
.	O

